Clinical Stage CAR-T for AL Amyloidosis and Select Immune-Mediated Diseases

Nexcella, Inc., a subsidiary of Immix Biopharma, announces poster presentation at the European Society for Blood and Marrow Transplantation and European Hematology Association 5th Annual European CAR T-cell Meeting

Updated clinical data for NXC-201, a next-generation CAR-T for multiple myeloma and AL amyloidosis, will be presented in Rotterdam, Netherlands February 9-11, 2023 LOS ANGELES, CA, Dec. 28, 2022 — Nexcella, Inc., a subsidiary of Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”) today announced that updated NXC-201 clinical data has been selected […]

Immix Biopharma in-licenses NXC-201, BCMA-targeted Next-Generation CAR-T Therapy Demonstrating High Complete Response Rate in Heavily Pre-Treated Multiple Myeloma (71% Complete Responses) and AL Amyloidosis (100% Complete Responses)

Multiple Myeloma – 85% overall response rate (71% CR/sCR) for NXC-201 at therapeutic dose in an ongoing Phase 1b study in 20 relapsed/refractory patients as of June 27, 2022 data cutoff (Haematologica https://doi.org/10.3324/haematol.2022.281628) AL Amyloidosis – 100% complete responses, 100% organ response rate for NXC-201 in 4 relapsed/refractory patients (Clinical Cancer Research https://doi.org/10.1158/1078-0432.CCR-22-0637) Potential first […]

ImmixBio Releases and Ships Scaled-Up GMP Batches of IMX-110 for Clinical Trial Patient Dosing

LOS ANGELES, CA, Dec. 12, 2022 — Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”), a biopharmaceutical company pioneering Tissue-Specific Therapeutics (TSTx)TM targeting oncology and immuno-dysregulated diseases, today announced that it has completed release testing and shipped Good Manufacturing Practice (“GMP”) process manufactured batches of IMX-110 for clinical trial patient dosing. IMX-110 was […]

Immix Biopharma Receives Institutional Review Board Approval to Enroll Pediatric Patients in Upcoming IMX-110 Clinical Trial, Key Requirement for U.S. Food and Drug Administration Approval of Rare Pediatric Disease Priority Review Voucher

Enrolling pediatric patients in a clinical trial is a key requirement for FDA approval of a Priority Review Voucher (“PRV”) While their future value is uncertain, PRVs are transferable to other companies and have historically sold for $67 to $350 million according to a January 2020 report on drug development by the Government Accountability Office […]

Immix Biopharma to Present Milestones Achieved to Enable Kick-Off of 2 IMX-110 Clinical Trials at the 2022 ThinkEquity Conference on October 26

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/fe1f9d2e-f230-494b-9bb9-6b910a14f2aa LOS ANGELES, Oct. 25, 2022 — Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”), a biopharmaceutical company pioneering Tissue-Specific Therapeutics (TSTx)™ targeting oncology and immuno-dysregulated diseases, today announced that Chief Executive Officer Ilya Rachman, MD, PhD, and Chief Financial Officer Gabriel Morris will present […]

ImmixBio Completes GMP Manufacturing of Scaled-Up Batch of IMX-110 for Clinical Trials

Scaled-up, proprietary GMP manufacturing process to be utilized in 2 clinical trials: 2022 planned monotherapy IMX-110 Clinical Trial in soft tissue sarcoma (“STS”) 2022 planned combination IMX-110 + BeiGene anti-PD-1 tislelizumab Clinical Trial in advanced solid tumors A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/49d68ad5-624b-46b9-8f15-cc07b6717d92 LOS ANGELES, Sept. 07, 2022 — Immix Biopharma, Inc. […]